CSIMarket
 
Exagen Inc   (XGN)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $1.9000 $-0.12 -5.941%
Day's High: $2.0223 Week Perf: -3.55 %
Day's Low: $ 1.85 30 Day Perf: -10.8 %
Volume (M): 49 52 Wk High: $ 3.92
Volume (M$): $ 93 52 Wk Avg: $2.31
Open: $2.02 52 Wk Low: $1.33



 Market Capitalization (Millions $) 34
 Shares Outstanding (Millions) 18
 Employees -
 Revenues (TTM) (Millions $) 52
 Net Income (TTM) (Millions $) 15
 Cash Flow (TTM) (Millions $) -40
 Capital Exp. (TTM) (Millions $) 1

Exagen Inc
Exagen Inc is a biotechnology company that specializes in developing and commercializing diagnostic tests for autoimmune diseases. The company focuses on leveraging advanced testing technologies and genomics to provide personalized medicine solutions for patients with complex autoimmune conditions. Exagen's tests help physicians in accurately diagnosing and monitoring patients, allowing for targeted treatment plans and improved disease management. Some of the diseases that Exagen's tests detect and monitor include lupus, rheumatoid arthritis, and autoimmune-related kidney diseases. The company aims to enhance patient outcomes and contribute to the advancement of precision medicine in the field of autoimmune diseases.


   Company Address: 1261 Liberty Way Vista, 92081 CA
   Company Phone Number: 560-1501   Stock Exchange / Ticker: NASDAQ XGN
   XGN is expected to report next financial results on March 19, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Exagen Inc

Exagen Inc. Reports Surprising $-0.31 Per Share Deficit Throughout Fiscal Year Ending September 30, 2023



Exagen Inc, a leading player in the Medical Laboratories sector, encountered a dip in revenue and suffered a greater financial shortfall in the fiscal period ending September 30, 2023. The company reported a loss of $-0.31 per share, while its revenue plummeted by -8.896% to $13.42 million compared to the same period in the previous year. In contrast, the Medical Laboratories sector as a whole recorded a revenue surge. These figures indicate a challenging business environment for Exagen Inc.
In the previous quarter, Exagen Inc generated a revenue of $14.14 million, with a bottom line of $-0.28 per share. However, in the fiscal period closing September 30, 2023, the company reported a net shortfall of $-5.415 million, a notable improvement from the deficit of $-8.096 million in the same quarter the prior year. Despite this improvement, Exagen Inc's financial performance remains cause for concern.

Exagen Inc

Exagen Inc Demonstrates Impressive Financial Growth and Improved Efficiency in Q1 2023

As a journalist, I have been studying the financial results of Exagen Inc and there are some very positive signs for the company in the first quarter of 2023. Firstly, the company?s ability to collect its outstanding accounts receivable from corporate clients has improved dramatically with a ratio of 5.34, which is above the company average. This indicates a healthy business climate in the Medical Laboratories industry and improving liquidity for customers during the first quarter of 2023.
Furthermore, the average receivable collection period for Exagen Inc in the March 31 2023 quarter has decreased to 68 days compared to 73 days in the Dec 31 2022 quarter. This indicates that the company is becoming more efficient and effective in its collections and suggests a solid level of financial discipline.






 

Exagen Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com